---
document_datetime: 2024-02-19 16:28:41
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/veoza-epar-all-authorised-presentations_en.pdf
document_name: veoza-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.6894557
conversion_datetime: 2025-12-22 10:20:17.843589
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) Number                                                      | (Invented) name         | Strength                | Pharmaceutical Form                                                         | Route of Administration             | Immediate Packaging                                                                                 | Pack size                                                                                                    |
|---------------------------------------------------------------------|-------------------------|-------------------------|-----------------------------------------------------------------------------|-------------------------------------|-----------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------|
| EU/1/23/1771/001 EU/1/23/1771/002 EU/1/23/1771/003 EU/1/23/1771/004 | Veoza Veoza Veoza Veoza | 45 mg 45 mg 45 mg 45 mg | Film-coated tablet Film-coated tablet Film-coated tablet Film-coated tablet | Oral use Oral use Oral use Oral use | blister (PA/alu/PVC/alu) blister (PA/alu/PVC/alu) blister (PA/alu/PVC/alu) blister (PA/alu/PVC/alu) | 28 x 1 tablets (unit dose) 30 x 1 tablets (unit dose) 100 x 1 tablets (unit dose) 10 x 1 tablets (unit dose) |